nu-derm system normal-dry

Manufacturer
OBAGI COSMECEUTICAL LLC | PURETEK CORPORATION | Swiss-American CDMO, LLC | G. S. Cosmeceutical USA, Inc.
Effective date
2025-03-14
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 21:27:32

Label at a glance#

Productnu-derm system normal-dry skin transformation
Active ingredientHYDROQUINONE, HOMOSALATE, OCTISALATE, ZINC OXIDE
Label structure23 sections

Indications and uses

For the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation.

Dosage and administration

A thin application should be applied once or twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring.

Storage and handling

store at controlled room temperature: 15°C–25°C (59°F–77°F) protect this product from excessive heat and direct sun

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

OBAGI NU-DERM®

SPL UNCLASSIFIED SECTION

Rx only

For external use only

DESCRIPTION

DESCRIPTION SECTION

Hydroquinone, USP 4% is 1, 4-benzenediol. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C6H6O2; molecular weight is 110.11 g/mol. The chemical structure is in the diagram below.

Chemical Structure
Chemical Structure

SPL UNCLASSIFIED SECTION

Each gram of Obagi Nu-Derm® Clear contains:

ACTIVE: Hydroquinone, USP 4% (40 mg/g)

INACTIVES: ascorbic acid, BHT, butylparaben, cetyl alcohol, disodium EDTA, glycerin, lactic acid, methylparaben, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, stearyl alcohol, tocopheryl acetate, water (aqua)

SPL UNCLASSIFIED SECTION

Each gram of Obagi Nu-Derm Blender® contains:

ACTIVE: Hydroquinone, USP 4% (40 mg/g)

INACTIVES: ascorbic acid, BHT, cetyl alcohol, disodium EDTA, glycerin, lactic acid, methylparaben, phenyl trimethicone, PPG-2 myristyl ether propionate, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, TEA-salicylate, tocopheryl acetate, water (aqua)

SPL UNCLASSIFIED SECTION

Each gram of Obagi Nu-Derm® Sunfader® contains:

ACTIVES: Hydroquinone, USP 4% (40mg/g); Octinoxate, USP 7.5%; Oxybenzone, USP 5.5%

INACTIVES: ascorbic acid, BHT, butylparaben, cetyl alcohol, disodium EDTA, glycerin, methylparaben, propylparaben, saponins, sodium lauryl sulfate, sodium metabisulfite, stearyl alcohol, tocopheryl acetate, water (aqua)

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunscreen agents such as those contained in Obagi Nu-Derm Sunfader® and Obagi Nu-Derm® Sun Shield Matte Broad Spectrum SPF 50.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and other unwanted areas of melanin hyperpigmentation.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS

WARNINGS SECTION

Hydroquinone is a skin-bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. Some users of this product may experience a mild skin irritation. If skin irritation becomes severe, stop use and consult a doctor. Close patient supervision is recommended.

WARNINGS: Avoid contact with eyes, nose, mouth and lips. In case of accidental contact, patient should rinse thoroughly with water and contact a physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS

PRECAUTIONS SECTION

(also see WARNINGS):

Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

PREGNANCY CATEGORY C

PREGNANCY SECTION

Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

NURSING MOTHERS

NURSING MOTHERS SECTION

It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

PEDIATRIC USAGE

PEDIATRIC USE SECTION

Safety and effectiveness in children below the age of 12 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and the physician notified immediately.

To report SUSPECTED ADVERSE REACTIONS, contact Obagi Cosmeceuticals LLC, at 1-800-636-7546 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A thin application should be applied once or twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring.

HOW SUPPLIED

HOW SUPPLIED SECTION

Obagi Nu-Derm® Clear is available as follows:
Net wt. 2 oz. (57 g) bottle
NDC 62032-101-36

Obagi Nu-Derm Blender® is available as follows:
Net wt. 2 oz. (57 g) bottle
NDC 62032-100-36

Net wt. 1 oz. (28 g) bottle
NDC 62032-100-10

Obagi Nu-Derm Sunfader® is available as follows:
Net wt. 2 oz. (57 g) bottle
NDC 62032-116-36

STORAGE AND HANDLING SECTION

Store at controlled room temperature: 15° to 25°C (59° to 77°F). Keep out of direct sunlight.

FigureFigure1-800-636-7546

SPL UNCLASSIFIED SECTION

Manufactured for:
Obagi Cosmeceuticals LLC,
Long Beach, CA 90806

All products/brand names, whether designated by notice or not (®/TM), are trademarks of Obagi Cosmeceuticals LLC and/or its affiliates.

©2019 Obagi Cosmeceuticals LLC.
All rights reserved. www.obagi.com

Revised 01/2019
9458404

Obagi Nu-Derm® Clear (Hydroquinone, USP 4%) Skin Bleaching Cream

Obagi Nu-Derm Blender® (Hydroquinone, USP 4%) Skin Bleaching Cream

Obagi Nu-Derm Sunfader® (Hydroquinone, USP 4%; Octinoxate, USP 7.5%; Oxybenzone, USP 5.5%) Skin Bleaching Cream with Sunscreens

SPL UNCLASSIFIED SECTION

Sun Shield Matte Broad Spectrum SPF 50
Net wt. 3 oz. (85 g) AM

SPL UNCLASSIFIED SECTION

Drug Facts

OTC - ACTIVE INGREDIENT SECTION

OTC - PURPOSE SECTION

Active ingredientsPurpose
Homosalate 10%Sunscreen
Octisalate 5%Sunscreen
Zinc Oxide 16.5%Sunscreen

Uses

INDICATIONS & USAGE SECTION

  • helps prevent sunburn
  • If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun

Warnings

WARNINGS SECTION

For external use only

OTC - DO NOT USE SECTION

Do not use on damaged or broken skin

OTC - STOP USE SECTION

Stop use and ask a doctor if rash occurs

OTC - WHEN USING SECTION

When using this product keep out of eyes. Rinse with water to remove.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Directions

DOSAGE & ADMINISTRATION SECTION

  • apply liberally 15 minutes before sun exposure
  • use a water resistant sunscreen if swimming or sweating
  • reapply at least every 2 hours
  • Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including:
    • limit time in the sun, especially from 10 a.m.–2 p.m.
    • wear long-sleeved shirts, pants, hats, and sunglasses
  • children under 6 months: Ask a doctor

Other information

STORAGE AND HANDLING SECTION

  • store at controlled room temperature: 15°C–25°C (59°F–77°F)
  • protect this product from excessive heat and direct sun

Inactive ingredients

INACTIVE INGREDIENT SECTION

Water (Aqua), C15-19 Alkane, Octyldodecyl Neopentanoate, Polymethylsilsesquioxane, Sorbitan Olivate, Silica, Polyglyceryl-6 Polyrininoleate, Sodium Chloride, Xanthan Gum, Glycerin, Hydroxyacetophenone, Disodium EDTA, 1,2-Hexanediol, Caprylyl Glycol, Sodium Hydroxide, Triethoxycaprylsilane, Polyhydroxystearic Acid, Disteardimonium Hectorite, Polyglyceryl-2 Isostearate, Euphorbia Cerifera (candelilla) Wax, Beeswax, Dimethicone

Questions or comments?

OTC - QUESTIONS SECTION

1.800.636.7546

Monday–Friday 9 a.m.–4 p.m. Pacific Time

SPL UNCLASSIFIED SECTION

Distributed by Obagi Cosmeceuticals LLC,
Long Beach, CA 90806

PRINCIPAL DISPLAY PANEL - Kit Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC# 62032-529-06

OBAGI®
MEDICAL

NORMAL DRY
Skin Transformation Kit

Principal Display Panel - Kit Carton
Principal Display Panel - Kit Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197795hydroquinone 4 % Topical CreamPSN3
197795hydroquinone 40 MG/ML Topical CreamSCD3
197795hydroquinone 4 % Topical CreamSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
HYDROQUINONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
c5cd4727-ac49-4409-82b1-5bd8006c3ec7Product name120171122
85490a6b-2306-6bf2-c51b-eb63537dc2daProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
62032-529-062025-03-14C16284748780-12cef2736-9e9a-d83d-e063-dadaa90ab31fOBAGI NU-DERM ® SYSTEM
62032-529-062025-01-30C16284748780-12cef2736-9e9a-d83d-e063-dadaa90ab31fOBAGI NU-DERM ® SYSTEM

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
62032-100-36nu-derm system normal-dry skin transformation57 g in 1 BOTTLE, PLASTICCREAM57 g40 mg in 1g3
62032-101-36nu-derm system normal-dry skin transformation57 g in 1 BOTTLE, PLASTICCREAM57 g40 mg in 1g3
62032-141-10nu-derm system normal-dry skin transformation85 g in 1 TUBELOTION85 g100 mg in 1g3
62032-529-06nu-derm system normal-dry skin transformation1 in 1 CARTONKIT13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
62032-100NU-DERM SYSTEM NORMAL-DRY SKIN TRANSFORMATION (HYDROQUINONE, OCTISALATE AND ZINC OXIDE) KIT [OBAGI COSMECEUTICAL LLC]3Current NDC, Legacy NDC20250316_7548658a-5371-4aed-baf8-e5dc54262223.zip
62032-101NU-DERM SYSTEM NORMAL-DRY SKIN TRANSFORMATION (HYDROQUINONE, OCTISALATE AND ZINC OXIDE) KIT [OBAGI COSMECEUTICAL LLC]3Current NDC, Legacy NDC20250316_7548658a-5371-4aed-baf8-e5dc54262223.zip
62032-141NU-DERM SYSTEM NORMAL-DRY SKIN TRANSFORMATION (HYDROQUINONE, OCTISALATE AND ZINC OXIDE) KIT [OBAGI COSMECEUTICAL LLC]3Unmatched20250316_7548658a-5371-4aed-baf8-e5dc54262223.zip
62032-529NU-DERM SYSTEM NORMAL-DRY SKIN TRANSFORMATION (HYDROQUINONE, OCTISALATE AND ZINC OXIDE) KIT [OBAGI COSMECEUTICAL LLC]3Current NDC, Legacy NDC, 4 package rows20250316_7548658a-5371-4aed-baf8-e5dc54262223.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 3 · 106 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 4 · 147 matching rows.

Source Document#

Source XML · Source PDF

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 8 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Obagi Nu-Derm System Normal-Oily Skin TransformationHYDROQUINONE, TITANIUM DIOXIDE, ZINC OXIDEObagi Cosmeceuticals LLCef3ddd1e-9305-42bb-a5f8-559e8e641d832025-11-05WarningsExact identifier
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc11 (package): 62032010136
ndc11 (package): 62032010036
Obagi Nu-Derm System Normal-Dry Skin TransformationHYDROQUINONE, TITANIUM DIOXIDE, AND ZINC OXIDEObagi Cosmeceuticals LLC750ea9a6-eedc-49db-8cef-1498ed41ad792025-11-04WarningsExact identifier
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc11 (package): 62032010136
ndc11 (package): 62032010036
Obagi Nu-Derm System Normal-Dry Skin Transformation KitHYDROQUINONE, HOMOSALATE, OCTISALATE, ZINC OXIDEObagi Cosmeceuticals LLC16efa2db-8172-4026-a519-08f53d68b3c92025-10-23WarningsExact identifier
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc11 (package): 62032010136
ndc11 (package): 62032010036
Obagi Nu-Derm System Normal-Oily Skin TransformationHYDROQUINONE, HOMOSALATE, OCTISALATE, ZINC OXIDEObagi Cosmeceuticals LLCe63327db-fb96-411c-945a-abe801d380452025-10-23WarningsExact identifier
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc11 (package): 62032010136
ndc11 (package): 62032010036
Obagi Nu-Derm System Normal-Oily Skin Transformation TrialHYDROQUINONE, HOMOSALATE, OCTISALATE, ZINC OXIDEObagi Cosmeceuticals LLC219c68dc-1e74-4136-9065-85466008d4452025-10-23WarningsExact identifier
ndc (package): 62032-101-36
ndc11 (package): 62032010136
Obagi Nu-Derm System Normal-Dry Skin Transformation TrialHYDROQUINONE, HOMOSALATE, OCTISALATE, ZINC OXIDEObagi Cosmeceuticals LLCe2c23345-69df-47a1-8e6b-b6225080d3632025-10-23WarningsExact identifier
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc11 (package): 62032010136
ndc11 (package): 62032010036
nu-derm system normal-dry skin transformationHYDROQUINONE, OCTISALATE AND ZINC OXIDEOBAGI COSMECEUTICAL LLC7548658a-5371-4aed-baf8-e5dc542622232025-03-14Warnings, Adverse reactionsExact identifier
ndc (package): 62032-141-10
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc (package): 62032-529-06
ndc (product): 62032-529
ndc11 (package): 62032010136
ndc11 (package): 62032010036
ndc11 (package): 62032052906
ndc11 (package): 62032014110
spl id: ed79404d-956a-4f71-b348-3e89930fac3d
spl set id: 7548658a-5371-4aed-baf8-e5dc54262223
NU-DERM BLENDER Skin Lightener and BlendingHYDROQUINONEObagi Cosmeceuticals LLCe5c450af-958e-41e3-9c2f-fda76b3596f52025-01-01Warnings, Adverse reactionsExact identifier
ndc (package): 62032-100-36
ndc (package): 62032-101-36
ndc (product): 62032-100
ndc (product): 62032-101
ndc11 (package): 62032010136
ndc11 (package): 62032010036

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.